Rituximab, Obinutuzumab, and Ofatumumab in CLL

(4:7)

Follicular Lymphoma: Obinutuzumab and Chemotherapy

(2:53)

Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial

(45)

Dr. Younes on Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma

(2:41)

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

(1:29)

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL

(1:39)

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCL

(4:23)

Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumab

(1:26)

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

(1:52)

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

(1:47)

Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib

(1:46)

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL

(59)

A Phase II single-arm study of obinutuzumab plus ibrutinib as frontline treatment for FL and MZL

(1:2)

Obinutuzumab + Venetoclax for Frontline CLL

(9:15)

CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil

(4:30)

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

(1:2)

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

(1:13)

Is obinutuzumab our key to improving the treatment of FL?

(2:46)

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL

(1:43)

Obinutuzumab plus venetoclax in early R/R DLBCL

(3:36)